Uses of Fossapower

Fossapower drug is made in the form of tablets with the main ingredient is Alendronate. The drug is used in the treatment of osteoporosis in many different subjects.

1 Fossapower tablet has the main ingredient is 13.06 mg Sodium Alendronate trihydrate (equivalent to 10mg alendronic acid) and excipients. Alendronate is an amino bisphosphonate, an active ingredient in the group of drugs that inhibit the activity of osteoclasts, helping to reduce and slow down the process of bone destruction that causes osteoporosis.
Indications for use of Fossapower:
Treatment of osteoporosis in postmenopausal women and men to prevent fractures; Treatment of glucocorticoid-induced osteoporosis with simultaneous suppression of bone loss in men and women on a risk basis as the disease progresses. Contraindications to the use of Fossapower:
People with esophageal abnormalities and other factors that can slow down the movement of the tablet through the esophagus, for example, the esophagus is not dilated or the esophagus is narrow; The person cannot stand or sit upright for 30 minutes; Hypersensitivity to any ingredient of Fossapower ; People with hypocalcemia; Pregnant and lactating women.

How to use:
To fully absorb Fossapower, the patient must take Fossapower for at least 30 minutes with only filtered water before using food, drink or any other medicine for the first time of the day. Other drinks (including mineral water), food, and some medications can decrease the body's ability to absorb Fossapower. This helps deliver the drug to the stomach effectively, thereby reducing the possibility of local irritation and irritation of the esophagus; Only take Fossapower tablets whole after waking up in the morning with a full glass of water (minimum 200ml of water); Patients should not let the medicine dissolve in the mouth and not chew the medicine, because it can cause mouth and throat ulcers; After taking Fossapower for at least 30 minutes, the patient should have breakfast and can lie down (do not lie down for less than 30 minutes after taking the drug); Do not use Fossapower at bedtime or before waking up in the morning (after taking it, go to sleep immediately); Patients can take vitamin D and calcium supplements if the diet does not provide enough. Dosage:
Treatment of osteoporosis in men and postmenopausal women: The recommended dose is 10mg/day; Treatment and prevention of glucocorticoid-induced osteoporosis: For postmenopausal women not using hormone replacement therapy (HRT) with estrogen, the recommended dose is 10 mg/day. For other patients including premenopausal and postmenopausal women taking HRT with estrogen, the recommended dose is 5mg once daily for men; Elderly: In clinical studies, there were no differences in the efficacy and safety of Fossapower when administered to the elderly and healthy adults. Therefore, it is not necessary to adjust the dose for the elderly; Patients with renal impairment: No dose adjustment is necessary for patients with a glomerular filtration rate (GFR) > 35ml/min. Fossapower should not be used in patients with renal failure with GFR < 35ml/min due to lack of clinical experience; Children: Fossapower has not been studied in children.

When using Fossapower, patients may experience some side effects such as:
Common: Stomach - intestines: Abdominal pain, flatulence, indigestion, diarrhea, constipation, esophageal ulceration, difficulty swallowing , acid reflux, abdominal distension; Musculoskeletal: Bone, muscle or joint pain; Nervous: Headache causing discomfort; Uncommon: Systemic: Erythema, pruritic rash; Gastro-intestinal: Gastritis, nausea, vomiting, esophagitis, erosive esophagitis; Rare: Systemic: Hypersensitivity reactions (including angioedema and urticaria). Transient symptoms such as malaise, myalgia, fever, mainly occurred at the time of initiation of treatment. Symptoms of hypocalcaemia are also sometimes severe, often occurring when the patient has pre-existing medical conditions. Stomach - intestines: narrowing of the esophagus, ulcers of the mouth - pharynx; Musculoskeletal: Severe musculoskeletal (muscle, bone, or joint) pain. There have been reports of osteonecrosis of the jaw in patients treated with bisphosphonates; In other senses: scleritis of the eye, sclerosing choroiditis, episcleritis. Very rare: Skin: Serious skin reactions including: Toxic epidermal necrolysis and Stevens - Johnson syndrome.

Some problems patients and family members need to pay attention to when using Fossapower:
Fossapower may cause local irritation of the upper stomach - intestinal mucosa, so caution should be taken when using the drug. for people with active upper gastrointestinal disease, eg: esophageal disease, dysphagia, duodenitis, gastritis or peptic ulcer. Esophageal reactions: Esophagitis, erosive esophagitis, esophageal ulceration, esophageal stricture or perforation may occur in patients receiving Fossapower. Doctors should pay attention to signs of esophageal reaction, instruct patients to stop taking Fossapower. Treatment may be discontinued if symptoms develop such as dysphagia, retrosternal pain, pain when swallowing, development of heartburn or worsening heartburn; The risk of serious esophageal side effects is higher for patients who do not use the medication correctly, who continue to use Fossapower after they have developed symptoms similar to esophageal irritation; There are some cases of gastric and duodenal ulcers, even serious complications, in patients taking Fossapower; Osteonecrosis of the jaw, often accompanied by tooth loss, and local infection (including osteomyelitis) has been reported in cancer patients on treatment regimens primarily using intravenous bisphosphonates. There are many patients who are using chemotherapy and corticosteroids; Osteonecrosis of the jaw may occur in osteoporosis patients receiving oral bisphosphonates; Consideration should be given to a dental examination and appropriate dental protection before initiating bisphosphonate therapy if the patient has concomitant risk factors (eg, cancer, chemotherapy, radiation therapy, Poor oral health, corticosteroids During treatment, patients should pay attention to avoid damaging their teeth if possible; Osteoarthritis and muscle pain may also be experienced in patients using bisphosphonates; Care should be taken Age and glucocorticoid use should be taken into consideration as these factors can cause osteoporosis; Hypocalcemia should be treated before starting alendronate. Minerals (eg, vitamin D deficiency and hypoparathyroidism) also need to be treated effectively.Patients need to control their serum calcium levels and hypercalcemia while taking Fossapower. positive effect of alendronate in increasing bone mineralization, possible hypophosphate and cal ci in serum; Fossapower medicine contains lactose, so it should not be used for patients with galactose intolerance, glucose-galactose intolerance, lactase deficiency; For pregnant and lactating women: Currently, Fossapower has not been studied in pregnant and lactating women, so it should not be used for this subject; Effects on ability to drive and use machines: There are no data to show that Fossapower affects the ability to drive and use machines.

Concomitant use of Fossapower with antacid calcium supplements and some other oral drugs will affect the absorption of Fossapower . Therefore, patients should be advised to wait at least 30 minutes after taking Fossapower before taking any other medicine.
During the use of Fossapower, the patient should pay attention to follow the instructions of the doctor. In addition, patients should carefully read the notes when using Fossapower to achieve the highest therapeutic effect.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.